{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:06Z","timestamp":1791489606733,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":257,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101451","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:40:43Z","timestamp":1789731643000},"page":"101451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patterns and outcomes of emergency department visits by patients receiving immune checkpoint inhibitors: a single-center, retrospective study"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2685-8860","authenticated-orcid":false,"given":"Taichi","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Sumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Someno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6154-5091","authenticated-orcid":false,"given":"Kazuhiro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8949-3407","authenticated-orcid":false,"given":"Shoko","family":"Satake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101451_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108873","article-title":"Immune checkpoint inhibition for the treatment of cancers: an update and critical review of ongoing clinical trials","volume":"232","author":"Akhbariyoon","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ctarc.2026.101451_bib0002","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101451_bib0003","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5415\/apallergy.0000000000000146","article-title":"From tumor to tolerance: a comprehensive review of immune checkpoint inhibitors and immune-related adverse events","volume":"14","author":"Sutanto","year":"2024","journal-title":"Asia Pac. Allergy."},{"key":"10.1016\/j.ctarc.2026.101451_bib0004","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1136\/emermed-2018-208091","article-title":"Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department","volume":"36","author":"Peyrony","year":"2019","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.ctarc.2026.101451_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2020.02.025","article-title":"Emergency presentations in patients treated with immune checkpoint inhibitors","volume":"130","author":"Cooksley","year":"2020","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.ctarc.2026.101451_bib0006","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.mayocpiqo.2021.09.007","article-title":"Clinical presentations and outcomes of patients receiving immune checkpoint inhibitors presenting to the emergency department","volume":"5","author":"Castillo","year":"2021","journal-title":"Mayo Clin. Proc. Innov. Qual. Outcomes."},{"key":"10.1016\/j.ctarc.2026.101451_bib0007","first-page":"1","article-title":"Immune-related adverse event in the emergency department: methodology of the immune-related emergency disposition index (IrEDi)","volume":"3","author":"Reyes-Gibby","year":"2024","journal-title":"Emerg. Cancer Care."},{"key":"10.1016\/j.ctarc.2026.101451_bib0008","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/emermed-2018-208206","article-title":"Challenge of immune-mediated adverse reactions in the emergency department","volume":"36","author":"Daniels","year":"2019","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.ctarc.2026.101451_bib0009","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2169\/internalmedicine.8919-21","article-title":"Atezolizumab-induced encephalitis in a patient with hepatocellular carcinoma: a case report and literature review","volume":"61","author":"Satake","year":"2022","journal-title":"Intern. Med."},{"key":"10.1016\/j.ctarc.2026.101451_bib0010","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2169\/internalmedicine.2429-23","article-title":"Severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in a man receiving immune checkpoint inhibitors for lung cancer","volume":"63","author":"Tanaka","year":"2024","journal-title":"Intern. Med."},{"key":"10.1016\/j.ctarc.2026.101451_bib0011","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101451_bib0012","series-title":"Common Terminology Criteria For Adverse Events (CTCAE), Version 5.0","year":"2017"},{"key":"10.1016\/j.ctarc.2026.101451_bib0013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctarc.2026.101451_bib0014","first-page":"2029","article-title":"Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors","volume":"29","author":"Guven","year":"2021","journal-title":"Support. Care Cancer."},{"key":"10.1016\/j.ctarc.2026.101451_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/emermed-2023-213605","article-title":"Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department","volume":"41","author":"Pini","year":"2024","journal-title":"Emerg. Med. J."},{"key":"10.1016\/j.ctarc.2026.101451_bib0016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.annemergmed.2018.04.019","article-title":"Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center","volume":"73","author":"El Majzoub","year":"2019","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.ctarc.2026.101451_bib0017","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajem.2025.07.057","article-title":"Underrecognized immune events in the emergency department among cancer patients on immune checkpoint inhibitors","volume":"97","author":"Y\u0131lmaz","year":"2025","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.ctarc.2026.101451_bib0018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/curroncol28010007","article-title":"Emergency department utilization for patients receiving immune checkpoint inhibitors: a retrospective analysis of identification and outcomes for those presenting for immune-related adverse events","volume":"28","author":"Holstead","year":"2020","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ctarc.2026.101451_bib0019","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1093\/ndt\/gfaa272","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ctarc.2026.101451_bib0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.clnesp.2025.10.031","article-title":"Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): the MOUSEION-012 systematic review and meta-analysis","volume":"70","author":"Vitale","year":"2025","journal-title":"Clin. Nutr. ESPEN."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:36:37Z","timestamp":1791488197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"alternative-id":["S2468294226003618"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101451","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns and outcomes of emergency department visits by patients receiving immune checkpoint inhibitors: a single-center, retrospective study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101451"}}